Understanding HIV Drug Resistance through Virtual Phenotypes
Author Information
Author(s): Swenson Luke C., Pollock Graham, Wynhoven Brian, Mo Theresa, Dong Winnie, Hogg Robert S., Montaner Julio S. G., Harrigan P. Richard
Primary Institution: BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada
Hypothesis
What is the distribution of inferred phenotypic HIV drug resistance values in clinical practice?
Conclusion
The study describes the distribution of virtual phenotypes in HIV patients, allowing for better interpretation of drug resistance in a clinical context.
Supporting Evidence
- The study included 5,277 patients with multiple samples, providing a robust dataset for analysis.
- Results showed a maximum change in IC50 of at least 13-fold for all drugs tested.
- Most patients had vPhenotypes below the lower clinical cut-off for most drugs.
Takeaway
This study looks at how HIV drugs work in patients who have had treatment failures, helping doctors understand how resistant the virus is to different medications.
Methodology
The study analyzed data from HIV-infected individuals enrolled in the British Columbia Drug Treatment Program, focusing on baseline plasma viral load and follow-up genotypic resistance results.
Limitations
The study is limited to a specific cohort in British Columbia and may not be generalizable to other populations.
Participant Demographics
HIV-infected adults enrolled in the British Columbia Drug Treatment Program from 1996 to 2008.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website